Person: KORTEN, VOLKAN
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
KORTEN
First Name
VOLKAN
Name
17 results
Search Results
Now showing 1 - 10 of 17
Publication Metadata only Susceptibility of bacterial isolates from Turkey - A report from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program(TAYLOR & FRANCIS LTD, 2007) KORTEN, VOLKAN; Eraksoy, H.; Basustaoglu, A.; Korten, V.; Kurt, H.; Ozturk, R.; Ulusoy, S.; Yaman, A.; Yuce, A.; Zarakolu, P.The study monitored the susceptibility of nosocomial pathogens to meropenem and comparator antimicrobial agents isolated as part of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program from Turkish university hospitals. In terms of minimum inhibitory concentration 90% (MIC90) values, meropenem was two- and eight-fold more active than imipenem against Escherichia coli and Klebsiella pneumoniae, respectively. 40.5% of K. pneumoniae, 23.1% of Klebsiella oxytoca and 15.3% of E. coli isolates were extended-spectrum P-lactamase (ESBL) producers. Piperacillin/tazobactam was the most active agent against isolates of Pseudomonas aeruginosa, followed by meropenem and imipenem. Against Acinetobacter baumannii isolates, meropenem and imipenem were the most active agents. Continued surveillance by the MYSTIC Program appears to be prudent to help focus on effective empiric treatment regimens.Publication Metadata only 11th European Congress on Clinical Microbiology and Infectious Diseases - Istanbul, Turkey, 2 April 2001 - Introduction(W B SAUNDERS CO LTD, 2002) KORTEN, VOLKAN; Finch, R; Korten, VPublication Metadata only Surveillance, control and management of infections in intensive care units in Southern Europe, Turkey and Iran - A prospective multicenter point prevalence study(W B SAUNDERS CO LTD, 2014) KORTEN, VOLKAN; Erdem, Hakan; Inan, Asuman; Altindis, Selma; Carevic, Biljana; Askarian, Mehrdad; Cottle, Lucy; Beovic, Bojana; Csomos, Akos; Metodiev, Krassimir; Ahmetagic, Sead; Harxhi, Arjan; Raka, Lul; Grozdanovski, Krsto; Nechifor, Mihai; Alp, Emine; Bozkurt, Fatma; Hosoglu, Salih; Balik, Ismail; Yilmaz, Gulden; Jereb, Matjaz; Moradi, Fatemeh; Petrov, Nikolay; Kaya, Selcuk; Koksal, Iftihar; Aslan, Turan; Elaldi, Nazif; Akkoyunlu, Yasemin; Moravveji, Seyyed Alireza; Csato, Gabor; Szedlak, Balazs; Akata, Filiz; Oncu, Serkan; Grgic, Svjetlana; Cosic, Gorana; Stefanov, Chavdar; Farrokhnia, Mehrdad; Mueller, Maria; Luca, Catalina; Koluder, Nada; Korten, Volkan; Platikanov, Viliyan; Ivanova, Petja; Soltanipour, Soheil; Vakili, Mahmood; Farahangiz, Saman; Afkhamzadeh, Abdorrahim; Beeching, Nicholas; Ahmed, Salman Shaheer; Cami, Alma; Shiraly, Ramin; Jazbec, Anja; Mirkovic, Tomislav; Leblebicioglu, Hakan; Naber, KurtObjective: We aimed to compare the features of intensive care units (ICUs), their antimicrobial resistance patterns, infection control policies, and distribution of infectious diseases from central Europe to Mid-West Asia. Methods: A cross-sectional point prevalence study was performed in 88 ICUs from 12 countries. Characteristics of ICUs, patient and antibiotic therapy data were collected with a standard form by infectious diseases specialists. Results: Out of 749, 305 patients at least with one infectious disease were assessed and 254 patients were reported to have coexistent medical problems. When primary infectious diseases diagnoses of the patients were evaluated, 69 had community-acquired, 61 had healthcare-associated, and 176 had hospital-acquired infections. Pneumonia was the most frequent ICU infection seen in half of the patients. Distribution of frequent pathogens was as follows: Enteric Gram-negatives (n = 62, 28.8%), Acinetobacter spp. (n = 47, 21.9%), Pseudomonas aeruginosa (n = 29, 13.5%). Multidrug resistance profiles of the infecting microorganisms seem to have a uniform pattern throughout Southern Europe and Turkey. On the other hand, active and device-associated infection surveillance was performed in Turkey more than Iran and Southeastern Europe (p < 0.05). However, designing antibiotic treatment according to culture results was highest in Southeastern Europe (p < 0.05). The most frequently used antibiotics were carbapenems (n = 92, 30.2%), followed by anti-gram positive agents (vancomycin, teicoplanin, linezolid, daptomycin, and tigecycline; n = 79, 25.9%), beta-lactam/beta lactamase inhibitors (n = 78, 25.6%), and extended-spectrum cephalosporins (n = 73, 23.9%). Conclusion: ICU features appears to have similar characteristics from the infectious diseases perspective, although variability seems to exist in this large geographical area. (C) 2013 The British Infection Association. Published by Elsevier Ltd. All rights reserved.Publication Metadata only Outcomes of Fecal Carriage of Extended-spectrum beta-Lactamase After Transrectal Ultrasound-guided Biopsy of the Prostate(ELSEVIER SCIENCE INC, 2014) ERTÜRK ŞENGEL, BUKET; Tigen, Elif Tukenmez; Tandogdu, Zafer; Ergonul, Onder; Altinkanat, Gulsen; Gunaydin, Bilal; Ozgen, Mahir; Sariguzel, Nevin; Sengel, Buket Erturk; Odabasi, Zekaver; Cek, Mete; Tokuc, Resit; Turkeri, Levent; Mulazimoglu, Lutfiye; Korten, VolkanOBJECTIVE To determine the prevalence of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae (PE) fecal carriage in patients that undergo transrectal ultrasonography-guided biopsy (TRUSbx) and its relationship with post-biopsy infections. METHODS A prospective clinical study in 4 different tertiary hospitals between 2008 and 2010 was conducted. Four hundred men with sterile urine who were to undergo a TRUSbx because of the suspicion of prostate cancer were included and followed for 14 days after biopsy. Rectal swab culture specimens were acquired immediately before the procedure. Demographic data, prophylaxis choice, quinolone or any other antibiotic consumption within the past 2 months, history of prostatitis, repeat biopsy, intensive care unit admission, hospitalization, urethral catheterization, diabetes mellitus (DM), and steroid usage were recorded. RESULTS ESBL carriage was detected in 19% of patients and quinolone use within the last 2 months; other antibiotic use within the last 2 months and DM were found to be significantly associated (P < .05). Symptomatic urinary tract infection (UTI) on the third day after biopsy was seen in 9% of patients and was associated with fluoroquinolone (FQ) consumption before biopsy. Although ESBL-PE carriage was associated with post-biopsy UTI symptoms, it was not found to be associated with post-biopsy symptomatic UTI. Urosepsis was seen in 2 patients (0.5%) after biopsy, and both the patients were ESBL-PE carriers. CONCLUSION The presence of ESBL-PE was associated with DM and FQ consumption before biopsy. ESBL-PE carriage was associated with a high rate of post-biopsy UTI symptoms requiring further elucidation; however, it was not associated with microbiologically proven infections. FQ consumption before TRUSbx was also associated with post-biopsy infections. (C) 2014 Elsevier Inc.Publication Metadata only Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program(ELSEVIER SCIENCE INC, 2007) KORTEN, VOLKAN; Korten, Volkan; Ulusoy, Sercan; Zarakolu, Pinar; Mete, BirgulThe Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program is a global study that provides antimicrobial susceptibility data in centers prescribing meropenem. The activity of meropenem and 7 broad-spectrum antimicrobials have been examined against 5208 bacterial isolates from 9 Turkish centers between 2000 and 2003. Cumulative susceptibility rates against all species of Enterobacteriaceae combined were ranked as follows: meropenem (99.3%), imipenem (97.6%), cefepime (80.0%), piperacillin-tazobactam (73.6%), ceftazidime (70.3%), ciprofloxacin (70.1%), cefotaxime (66.9%), and tobramycin (67.2%). The production of extended-spectrum beta-lactamases (ESBLs) was detected in 48.7% of Klebsiella pneumoniae and in 19.5% of Escherichia coli isolates. Of ESBL producing K. pneumoniae isolates, 75.7% were resistant to tobramycin, 40.3% to ciprofloxacin, and 48.3% to piperacillin-tazobactam. Only piperacillin/ tazobactam and carbapenems were active against more than 50% of Pseudomonas aeruginosa at the National Committee for Clinical Laboratory Standards-susceptible breakpoint, and the carbapenems were the most active compounds against Acinetobacter spp. These data confirm the continued potency of meropenem against Enterobacteriaceae in units where it is actively being prescribed. (c) 2007 Elsevier Inc. All rights reserved.Publication Metadata only Influence of oral glycopeptides on the fecal flora of human volunteers: Selection of highly glycopeptide-resistant enterococci(Oxford University Press, 1996) KORTEN, VOLKAN; Van Der Auwera P., Pensart N., Korten V., Murray B.E., Leclercq R.Changes in fecal flora were evaluated in 22 healthy volunteers administered oral vancomycin or teicoplanin in 1989-1991 in Belgium. Evaluation of 5 colonies per subject revealed no glycopeptide-resistant enterococci in the predominant flora before glycopeptide administration; however, large numbers (mostly Enterococcus faecium) emerged by the end of the study in 14 (64%) of the subjects. Pediococci and lactobacilli also increased in number. In 1992, 40 healthy volunteers and 33 cancer patients were evaluated by plating stool samples directly onto selective media containing vancomyein; low numbers of vancomycin-resistant enterococci (<50 cfu/g) were found in 11 (28%) of the 40 and 4 (12%) of the 33 samples, respectively. DNA restriction fragment length polymorphism analysis showed that most isolates were different, but all contained vanA in Tn1546-like elements. These results indicate that vanA and Tn1546-like elements were common in Belgium as early as 1989 and that community-based individuals in that location likely form a major reservoir for glycopeptide-resistant enterococci.Publication Metadata only Doripenem: A new carbapenem in clinical practice [Doripenem: Klinik uygulamada yeni bir karbapenem](DOC Design and Informatics Co. Ltd., 2010) KORTEN, VOLKAN; Başaran S., Korten V.Doripenem is the newest addition to the carbapenems, the most active class of antibiotics against many resistant pathogens. This review focuses on the antimicrobial, pharmacological and clinical aspects of doripenem. Its spectrum of activity is similar to that of meropenem and imipenem. According to the Turkish data of comparative activity of carbapenem (COMPACT) study, doripenem inhibited 64% of Pseudomonas aeruginosa at MIC 2 μg/ml, whereas meropenem and imipenem inhibited 56.2%, and 48.2% of the isolates, respectively. Unlike imipenem or meropenem, doripenem is stable for 12 hours at room temperature and may be delivered safely as a 4-hour extended infusion. This practice of administration lengthens the duration of time that the concentration of doripenem remains above the MICs of less susceptible pathogens. Based on animal models, doripenem has less epileptogenic activity than imipenem. Doripenem has been approved for use in treatment of complicated intraabdominal infection, complicated urinary tract infection, hospital-acquired pneumonia, and ventilator-associated pneumonia that are caused by susceptible pathogens.Publication Metadata only Subcutaneous nodules caused by Pseudomonas aeruginosa: healing without incision and drainage(1992) KORTEN, VOLKAN; Korten, V.; Gürbüz, O.; Firatli, T.; Bayik, M.; Akoglu, T.In a patient with multiple myeloma, numerous indurated, subcutaneous nodules and pyomyositis due to Pseudomonas aeruginosa were noted. These lesions resolved with ciprofloxacin plus ceftazidime therapy without surgical incision and drainage. Despite another course of cancer chemotherapy after total disappearance, there were no recurrences at the end of 3 months. Quinolones initially combined with other antipseudomonal beta-lactam agents may be the drugs of choice in the management of patients with subcutaneous nodules caused by P. aeruginosa.Publication Metadata only Impact of the Fluoroquinolones on Gastrointestinal Flora(1993) KORTEN, VOLKAN; Korten V., Murray B.E.A number of studies have been performed to evaluate the effect of the fluoroquinolones on gastrointestinal flora. The fluoroquinolones have only slight or no effect on the oropharyngeal flora, except when Neisseria, Haemophilus or Branhamella spp. are present. Studies have consistently shown that Gram-negative facultative bacteria of the lower intestinal flora are strongly suppressed during administration of these agents. Total faecal anaerobes are generally unchanged. The effect of the fluoroquinolones on Gram-positive bacteria is more variable with mild to moderate suppression reported with some agents. In view of the high faecal concentrations of the fluoroquinolones, the general lack of effect on anaerobes is surprising; it may be attributable to the large number of microorganisms found in faeces and faecal binding of the fluoroquinolones. Several recent studies suggest that the effects of some fluoroquinolones on faecal anaerobes and Gram-positive cocci may be more profound in certain patient populations such as bone marrow transplant recipients and patients undergoing gastrointestinal surgery. Colonisation with yeasts and the emergence of resistant bacterial strains have been reported during or after fluoroquinolone administration in some studies. Future studies will need to investigate the effect of the newer agents with greater activity against anaerobes and Gram-positive cocci on the gastrointestinal flora and to continue surveillance for resistant organisms. © 1993, ADIS International Limited. All rights reserved.Publication Metadata only Giant Purulent Pericarditis with Cardiac Tamponade Due to Streptococcus intermedius Rapidly Progressing to Constriction(WILEY-BLACKWELL, 2015) TİGEN, ELİF; Tigen, Elif T.; Sari, Ibrahim; Ak, Koray; Sert, Sena; Tigen, Kursat; Korten, VolkanPurulent pericardial effusion, although rare, is a life-threatening condition usually produced by the extension of a nearby bacterial infection locus or by blood dissemination in the immune-suppressed subjects or in the course of cardiothoracic surgery. Because clinical features of purulent pericardial effusion are often nonspecific, it can cause delay in diagnosis. Therefore, a high index of suspicion is required for timely diagnosis and management. Herein, we describe a case of giant purulent pericardial effusion due to Streptococcus intermedius with the history of bronchiectasis and pneumonia, which was successfully treated with pericardiocentesis via parasternal approach, appropriate antibiotics, and pericardiectomy. Mini-Abstract Purulent pericardial effusion, although rare, is a life-threatening condition usually produced by the extension of a nearby bacterial infection locus or by blood dissemination in the immune-suppressed subjects or in the course of cardiothoracic surgery. Because clinical features of purulent pericardial effusion are often nonspecific, it can cause delay in diagnosis. Therefore, a high index of suspicion is required for timely diagnosis and management. Herein, we describe a case of giant purulent pericardial effusion due to Streptococcus intermedius with the history of bronchiectasis and pneumonia, which was successfully treated with pericardiocentesis via parasternal approach, appropriate antibiotics, and pericardiectomy.